drugset / Trial / NCT02902965
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
Phase 2
Completed
74 enrolled
Pharmacyclics Switzerland GmbH
Janssen Research & Development, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2 open-label study to evaluate the efficacy and safety of ibrutinib in combination with bortezomib and dexamethasone for patients with relapsed or relapsed and refractory multiple myeloma.
Timeline
- Start
- 2016-09-20
- Primary completion
- 2018-10-26
- Completion
- 2018-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | 840 mg | Oral |
| Background | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |